Oncology – Skin
Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer version 8 validated in two independent cohorts.
23 Jun, 2022 | 09:57h | UTC
ASCO Guideline Update: Systemic therapy for melanoma.
14 Jun, 2022 | 11:00h | UTC
Systematic Review: Artificial intelligence and machine learning algorithms for early detection of skin cancer in community and primary care settings.
10 Jun, 2022 | 10:28h | UTC
Commentary on Twitter
NEW Review: '#ArtificialIntelligence and #MachineLearning algorithms for early detection of #skincancer in community and primary care settings: a systematic review'. @Cambridge_Uni @OUHospitals @UniMelb @UniofNottingham @QMUL_WIPH https://t.co/LQuzNbrKpn pic.twitter.com/v83GDEg2G4
— The Lancet Digital Health (@LancetDigitalH) May 26, 2022
RCT: Effect of reflectance confocal microscopy for suspect lesions on diagnostic accuracy in melanoma.
2 Jun, 2022 | 10:41h | UTC
Commentary on Twitter
In this RCT, adjunctive use of reflectance confocal microscopy for suspicious lesions is proven to reduce unnecessary excisions and removes all aggressive melanomas at baseline in a real-life, prospective clinical decision making setting. https://t.co/cWJu9TlaEH
— JAMA Dermatology (@JAMADerm) June 1, 2022
Review: Managing metastatic melanoma in 2022.
19 May, 2022 | 10:23h | UTCManaging Metastatic Melanoma in 2022: A Clinical Review – JCO Oncology Practice
Commentary on Twitter
Managing Metastatic #Melanoma in 2022: Clinical Review
A comprehensive guide to past, present, and future therapeutic approaches for patients with #advancedmelanoma. https://t.co/lh02gmmY27 #melsm #JCOOP @BenSwitzerDO pic.twitter.com/8V4bqcsMGT
— JCO Oncology Practice (@JCOOP_ASCO) February 23, 2022
Cohort Study: Recurrence and mortality risk of Merkel cell carcinoma by cancer stage and time from diagnosis.
5 May, 2022 | 10:14h | UTCRecurrence and Mortality Risk of Merkel Cell Carcinoma by Cancer Stage and Time From Diagnosis – JAMA Dermatology (link to abstract – $ for full-text)
Author Interview: Recurrence and Mortality Risk of Merkel Cell Carcinoma by Cancer Stage and Time From Diagnosis
News Release: Patients with rare skin cancer, Merkel cell carcinoma, face 40% recurrence rate – University of Washington School of Medicine
Commentary on Twitter
In this cohort study, Merkel cell carcinoma (MCC) recurrence rate was 40%, more than 90% of MCC recurrences arose within 3 years. https://t.co/46rDnVtyHh
— JAMA Dermatology (@JAMADerm) February 23, 2022
Guidelines: Cutaneous lymphomas.
25 Apr, 2022 | 00:38h | UTC
RCT: Pembrolizumab vs. placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma.
4 Apr, 2022 | 00:56h | UTCPembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Global burden of cutaneous melanoma in 2020 and projections to 2040.
31 Mar, 2022 | 08:11h | UTCGlobal Burden of Cutaneous Melanoma in 2020 and Projections to 2040 – JAMA Dermatology (free for a limited period)
Editorial: Melanoma Epidemiology—Pivoting to Low- and Middle-Income Countries (free for a limited period)
Commentary: Global Burden of Melanoma Considerable, Set to Rise by 2040 – HealthDay
Review | Imaging findings of malignant skin tumors: radiological–pathological correlation.
25 Mar, 2022 | 08:40h | UTC
Estimating overdiagnosis of melanoma using trends among black and white patients in the US.
24 Mar, 2022 | 08:52h | UTCEstimating Overdiagnosis of Melanoma Using Trends Among Black and White Patients in the US – JAMA Dermatology (link to abstract – $ for full-text)
Commentary: Deadly form of skin cancer ‘overdiagnosed’ in some patients, study finds – UPI
Commentary from the author on Twitter (thread – click for more)
The wildest thing about this paper is we wrote it in 2017, then shelved it because of the initial push back in peer review. This experience taught me A LOT about when colleagues are ready to accept ideas that challenge their thinking. 🧵
1/9 https://t.co/hXDURXkwju— Ade Adamson, MD MPP (@AdeAdamson) March 20, 2022
Vitamin B3, niacinamide and reducing skin cancer risk: what does the research say?
22 Mar, 2022 | 08:03h | UTC
NCCN Guidelines Insights: Squamous Cell Skin Cancer, Version 1.2022.
7 Feb, 2022 | 08:34h | UTC
Guideline: atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS).
3 Feb, 2022 | 08:48h | UTC
RCT: Sirolimus plus prednisolone vs. sirolimus monotherapy for kaposiform hemangioendothelioma.
18 Jan, 2022 | 09:08h | UTCSirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial – Blood (link to abstract – $ for full-text)
RCT: In patients with untreated advanced melanoma, treatment with Relatlimab plus Nivolumab was associated with increased median progression-free survival compared with Nivolumab alone (10.1 months vs. 4.6 months).
12 Jan, 2022 | 08:43h | UTCRelatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
The inhibition of two immune checkpoints, LAG-3 and PD-1, provided a greater benefit with regard to PFS than inhibition of PD-1 alone in patients with previously untreated metastatic or unresectable melanoma. https://t.co/idtOgksg74 pic.twitter.com/vx1W9O4Dh6
— NEJM (@NEJM) January 5, 2022
RCT: Long-term outcomes with Nivolumab plus Ipilimumab or Nivolumab alone vs. Ipilimumab in patients with advanced melanoma.
5 Dec, 2021 | 23:07h | UTCEditorial: CheckMate-067: Raising the Bar for the Next Decade in Oncology – Journal of Clinical Oncology
Original Study: #ESMO19 – Randomized Trial: Improved Overall Survival at 5 Years with Combined Immunotherapy for Advanced Melanoma
Guideline on Cutaneous Angiosarcomas – Update 2021.
26 Nov, 2021 | 10:00h | UTCS1-Guideline Cutaneous Angiosarcomas – Update 2021 – Journal of the German Society of Dermatology
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab.
16 Nov, 2021 | 08:14h | UTCLong-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)
Original Study: Study: Combination Immunotherapy for Melanoma Brain Metastases
RCT: Overall survival benefit with Tebentafusp in metastatic uveal melanoma.
28 Sep, 2021 | 09:03h | UTC
Commentary on Twitter
Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma. https://t.co/HnSdWItKIp pic.twitter.com/qu4huRn3Mu
— NEJM (@NEJM) September 27, 2021
Viewpoint: Sentinel lymph node biopsy in cutaneous melanoma—where do we stand?
22 Aug, 2021 | 22:16h | UTCSentinel Lymph Node Biopsy in Cutaneous Melanoma—Where Do We Stand? – JAMA Dermatology (free for a limited period)
US Report: Death rates are declining for many common cancers, including lung cancer and melanoma.
15 Jul, 2021 | 09:11h | UTCCommentaries: Death rates are declining for many common cancers in the U.S., report finds – STAT AND Annual report to the nation: Rapid decrease in lung cancer and melanoma deaths – American Cancer Society
Viewpoint | Active surveillance as a management option for low-risk basal cell carcinoma.
15 Jun, 2021 | 08:49h | UTC
An epidemic of overdiagnosis: Melanoma diagnoses sky rocket
20 Jan, 2021 | 01:30h | UTCAn epidemic of overdiagnosis: Melanoma diagnoses sky rocket – Brigham and Women’s Hospital AND Does Screening for Skin Cancer Result in Melanoma Overdiagnosis? – Univadis
Original study: The Rapid Rise in Cutaneous Melanoma Diagnoses ($)
Related: Overdiagnosis: what it is and what it isn’t – BMJ Evidence Based Medicine (free) AND Overdiagnosis across medical disciplines: a scoping review – The BMJ Open (free) AND Too much medical care: bad for you, bad for health care systems – STAT News (free) AND Screening: How overdiagnosis and other harms can undermine the benefits – Health News Review (free) AND Overdiagnosis: causes and consequences in primary health care – Canadian Family Physician (free) AND Five warning signs of overdiagnosis – The Conversation (free) AND What is overdiagnosed cancer? And why does it matter? – Croakey (free) AND Blame rising cancer overdiagnosis on ‘irrational exuberance’ for early detection – STAT (free) AND Preventing overdiagnosis and the harms of too much sport and exercise medicine – British Journal of Sports Medicine (free)